Plandai Biotechnology, Inc. Receives Approval to Grow Cannabis for Medical Research From Uruguay's Ministry of Public Health

SEATTLE, WA--(Marketwired - October 29, 2014) - Plandaí Biotechnology, Inc. (OTCQB: PLPL) ("Plandaí" or "the Company"), a developer of highly bioavailable plant extracts for industries including health, wellness, nutriceutical, and pharmaceutical, today announced that Uruguay's Ministry of Public Health has approved an academic collaboration between Plandaí and the Group of Medicinal Chemistry from the School of Science at the University of the Republic ("University") in Montevideo, Uruguay. The approval, issued in September 2014, allows Plandaí to grow cannabis in conjunction with the University, for medical research, which will be undertaken by students and scientists from the School of Science at the University.

Plandaí Biotechnology - Uruguay, SA, a wholly owned subsidiary of Plandaí Biotechnology, is currently the only company given authorization to grow cannabis and conduct medical research in Uruguay. Published research indicates that Plandaí's proprietary extraction process should render the complete cannabinoid complex from the live plant while retaining the acid forms of THC, which are devoid of psychotropic effects. The result should be a highly bioavailable extract that retains all of the potential medical benefits of cannabis without the psychoactive properties. Plandaí intends to establish a pharmaceutical platform in once the initial scientific investigations have been successfully completed.

This research project is scheduled to take place over a 3-year period beginning early 2015. The first phase of the project will establish the infrastructure and protocols for growing the cannabis in a controlled environment to ensure genetic purity and chemical consistency. A team of academics at the University will then collaborate with Plandaí's scientists to test the cannabinoid complex for potential benefit for treating neuron disorders, cancers and concussion injuries through animal testing. However, before the Company can conduct human clinical trials, prior approval from Uruguay's Ethics Committee and Medicine Council will be required.

The University of the Republic is a State institution founded in 1849. With several campuses throughout the city of Montevideo, the university provides an academic platform to more than 80,000 students.

About Plandaí Biotechnology, Inc.
Plandaí Biotechnology, Inc. and its subsidiaries develop highly bioavailable, phytonutrient rich extracts which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Plandaí Biotechnology, through its South African subsidiaries, controls every aspect of production, from growing specific raw materials such as green tea on its farms to producing its proprietary Phytofare^™ extract, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. The manufacturing facility has also been engineered for citrus fruits and the recovery of limonoids. Targeted industries for the Company's products include beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical. For more information, please visit http://www.plandaibiotech.com.

Safe Harbor Statement
The information provided may contain forward-looking statements and involve risks and uncertainties. Results, events and performances could vary from those contemplated. These statements involve risks and uncertainties which may cause actual results, expressed or implied, to differ from predicted outcomes. Risks and uncertainties include product demand, market competition, and Plandaí's ability to meet current or future plans. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Plandaí is not obliged to publicly release revisions to any forward-looking statement, to reflect events or circumstances afterward, or to disclose unanticipated occurrences, except as required under applicable laws.